Ofloxacin: in-vitro activity against clinical isolates.
The in-vitro activity of ofloxacin, a new quinolone derivative, was evaluated in 273 bacterial strains isolated from urine. The results showed a remarkable activity against most Gram-negative bacteria and, in particular, against Enterobacter aerogenes, which is very difficult to eradicate even with third-generation cephalosporins.
D001437:Bacteriuria; D004352:Drug Resistance, Microbial; D004754:Enterobacter / Q000187:drug effects; D004755:Enterobacteriaceae / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin; D010078:Oxazines / Q000494:pharmacology*; D011513:Proteus mirabilis / Q000187:drug effects; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D012706:Serratia marcescens / Q000187:drug effects
D010078:Oxazines; D015242:Ofloxacin